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Résumé en
anglais
CONTEXT: Ectopic GHRH secretion is a rare cause of acromegaly, and case reports
are mainly isolated.SETTING: From the registry of the sole laboratory performing
plasma GHRH assays in France, we identified cases of ectopic GHRH secretion
presenting with acromegaly between 1983 and 2008. PATIENTS: Twenty-one
patients aged 14-77 yr were identified from 12 French hospitals. Median GHRH was
548 (270-9779) ng/liter. MAIN OUTCOME MEASURES: Outcome measures included
description of tumor features and outcome and the relation between plasma GHRH
values and tumor site, size, and spread. RESULTS: The primary neuroendocrine
tumor was identified for 20 of 21 patients (12 pancreatic, seven bronchial, one
appendicular). Tumors were large (10-80 mm), identified on computed tomography
scan in 18 cases and by endoscopic ultrasound and somatostatin receptor
scintigraphy in two. Somatostatin receptor scintigraphy had a similar sensitivity to
computed tomography scan (81 vs. 86%). Tumors were all well differentiated; 47.6%
had metastasized at the time of diagnosis of acromegaly. After a median follow-up of
5 yr, 85% of patients were alive. Ninety-one percent of patients whose tumor was
completely removed were considered in remission, and most had normalized plasma
GHRH. The remaining patients were treated with somatostatin analogs: IGF-I
normalized except for one patient who required pegvisomant, but GHRH levels
remained elevated. No correlations were found between GHRH levels and tumor site
or size or the existence of metastases. Identification of increased plasma GHRH
during follow-up was an accurate indicator of recurrence. CONCLUSIONS: The
prognosis of endocrine tumors responsible for GHRH secretion appears relatively
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